

17th October, 2019

(1) BSE Ltd
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Scrip Code: 500087

Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Sub: Press Release

Dear Sir/Madam,

Please find enclosed press release dated 17th October, 2019, regarding acquisition of a novel and patented anti-infective asset, Elores, from Venus Remedies Limited.

Kindly acknowledge the receipt.

Thank you,

Yours faithfully,
For Cipla Limited



Rajendra Chopra
Company Secretary



Encl: as above

Prepared by: Mandar Kurghode

Cipla acquires novel anti-infective Elores to further anti-microbial stewardship in critical care in India

- **Product to strengthen Cipla's historic leadership in the anti-infectives space in India, and reinforce play in the Indian branded market**
- **Acquisition in keeping with Cipla's legacy of access to life-saving drugs and work in anti-microbial stewardship**

Mumbai, India; October 17, 2019: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; hereafter referred to as "Cipla") announces the acquisition of a novel and patented anti-infective product, Elores, from Venus Remedies Limited ("VRL") for the Indian market to further strengthen its presence in the branded Indian critical care space and as a part of its agenda to contribute to the fight against Anti-Microbial Resistance (AMR).

Elores is a novel combination of Ceftriaxone (a third generation beta-lactam cephalosporin), Sulbactam (a beta-lactamase inhibitor) and Disodium EDTA (an Antibiotic Resistance Breaker) indicated for the treatment of life threatening infections caused by gram-negative bacteria. It preserves the efficacy of the antibiotic using appropriate Antibiotic Resistance Breakers (ARBs). The product was launched in India across select tertiary care hospitals in the country in 2013 after approval from the Drug Controller General of India.

AMR has emerged as a critical threat to public health. At the present rate, it is estimated that as many as 10 million individuals worldwide could die annually from complications related to AMR. India carries one of the largest burdens of drug-resistant pathogens worldwide. In India, Cipla has a long history of antibiotic development from ampicillin in the 1970s to quinolones in the 1990s. More recently, Cipla introduced the extremely effective antibiotic colistin in India. Today, Cipla is the market leader in the anti-infectives segment in India, and has a large portfolio of oral and injectable anti-microbial brands that serve over 20 million patients every year. Elores will strengthen Cipla's play in branded anti-infectives. With the view to partner with patients and physicians in infection management, Cipla recently launched the 'Save Susceptibility' campaign to build awareness, enable better diagnosis and enable appropriate action and use of anti-microbials.

Umang Vohra, Managing Director and Global Chief Executive Officer, Cipla, said: "Cipla has consistently been at the forefront of promoting rational and judicious use of antibiotics, and has been a leading industry voice in the fight against AMR. Elores underscores our commitment to

anti-microbial stewardship and is a significant addition to our branded portfolio of anti-infectives in India. We recently acquired ZEMDRI™, and with the acquisition of Elores, we have added to our offering of new generation antibiotics. In keeping with our purpose of Caring for Life, Elores will improve patient access to innovative quality medicines and help patients battle life-threatening resistance at critical junctures."

Saransh Chaudhary, CEO, Venus Medicine Research Centre, said: "VRL has been leading the research on novel anti-infectives in India. We've always viewed anti-microbial resistance (AMR) as a huge public health crisis that needs to be dealt with immediately and at all levels of the healthcare setup. Elores was our response to the problem and it has been very satisfying to see the difference that it has made in the lives of patients. I'm positive that Cipla will expand the reach of Elores to many more patients in India while ensuring a similar commitment to anti-microbial stewardship. AMR continues to be the core focus for us going forward and we hope that our consistent efforts in this space will lead to better outcomes for patients dealing with life-threatening infections."

-----ENDS-----

About Elores

Elores is a novel combination of Ceftriaxone (third generation beta-lactam cephalosporin), Sulbactam (beta-lactamase inhibitor) and Disodium EDTA (Antibiotic Resistance Breaker), and it restores the in vitro activity of Ceftriaxone against ESBL/MBL producing gram-negative bacteria, including enzyme families that belong to Ambler class A (TEM, SHV, CTX-M), class B (NDM, VIM, IMP), class C (some variants of AmpC), and class D (OXA ESBLs). In the recently concluded Phase-3 clinical trial, Elores was proven to be non-inferior to Meropenem for the treatment of patients suffering from complicated urinary tract infections, including acute pyelonephritis.

About Antibiotic Resistance Breakers (ARBs)

ARBs, sometimes referred to as antibiotic adjuvants, are non-antibiotic moieties which do not have any anti-microbial activity on their own, but in combination with antibiotics enhance their anti-microbial activity and help overcome resistance barriers by reducing the Minimum Inhibitory Concentration (MIC).

About Cipla's work in AMR

Elores is the latest milestone in Cipla's history of proactive and humanitarian leadership in enabling access to life-saving drugs. Cipla has been at the forefront of anti-microbial stewardship. In July



this year, Cipla USA, Inc., announced the acquisition of the worldwide rights (excluding Greater China) of ZEMDRI™, a once-daily novel intravenous (IV) aminoglycoside for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, in adults who are unresponsive to currently available treatment options due to AMR. Cipla is also a signatory to the Industry Declaration on AMR at the World Economic Forum in Davos in 2016 that laid out a roadmap to combat AMR. An independent analysis released by the Access to Medicine Foundation in January 2018 identified Cipla as one of the drug-makers leading the effort to curb overuse of antibiotics, and implement production and source systems that help prevent environmental release of antibiotics¹. Its Antibiotic Benchmark Report recognised Cipla for its work in educating healthcare practitioners (HCPs), illustrating AMR trends in marketing material, adapting packaging to support rational use, and engaging in AMR surveillance².

About Cipla:

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT June'19) and is the 3rd largest in the pharma private market in South Africa (IQVIA MAT June'19). For over eight decades, making a difference to patients has inspired every aspect of Cipla's work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of 'Caring for Life' and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders. For more, please visit [Cipla](#), or click on [Twitter](#), [Facebook](#), [LinkedIn](#).

For queries, please contact:

Corporate Communications

Heena Kanal

Investor Relations

Naveen Bansal

¹ For more: <https://accesstomedicinefoundation.org/newsroom/superbugs-first-independent-comparison-of-pharma-companies-efforts-to-address-drug-resistant-infections> (last accessed July 21, 2019)

² For more: <https://accesstomedicinefoundation.org/amr-benchmark/case-studies/case-3-broad-generic-antimicrobial-portfolio-CIPLA> (last accessed July 21, 2019)

About Venus Remedies Limited (VRL):

Established in 1989 in Panchkula, India, Venus Remedies Limited is a research based pharmaceutical company and is among the leading global injectable manufacturers, possessing a wide product basket catering to high-growth therapeutic segments of anti-microbial resistance, oncology, skin & wound care and pain management, with an expansive global footprint extending over 60 nations. VRL has a rich portfolio of both research and generic products with more than 100 patent grants and 600+ marketing authorizations worldwide. VRL's manufacturing units are accredited with many national and international certifications for Good Manufacturing Practices (GMPs) such as European GMP, Australian GMP, Saudi Arabia, Thailand and from many other leading global regulatory authorities. Besides, Venus Medicine Research Centre, a DSIR-approved, GLP-accredited, state-of-the-art research center, is committed to bring to the world novel breakthroughs that cater to critical care and super specialty segments. Patients are at the core of our thinking and we make sure that our efforts do not end with developing a new product or therapy but extend beyond to provide a holistic solution to the patients.